1. In Vivo

Gastrotech Pharma AS

 
• By Melanie Senior

Denmark's Gastrotech Pharma is harnessing gastro-intestinal hormones such as ghrelin and GLP-1 to develop more effective therapies for irritable bowel syndrome and cachexia.

Gastrotech Pharma AS was founded in 2003 around IP generated by the University of Gothenburg in Sweden. It came about after a meeting between the partners at venture capital firm Nordic Biotech, and the management of Sahltech AB, a holding company set up to commercialize IP generated by the Sahlgrenska Academy, Gothenburg University's medical faculty, and the Karolinska Institute in Stockholm. (Sahltech also cultivated much of the IP behind stem cell firm Cell Therapeutics, now known as Cellartis AB .)

Gastrotech's surprisingly advanced pipeline--it has two Phase II programs—is focused on gastro-intestinal (GI) disorders including irritable bowel syndrome (IBS) and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.